Bio-Techne to Be Acquired by Merck for $73 Per Share in All-Cash Merger

Bio-Techne has entered into an agreement to be acquired by Merck, Darmstadt, Germany, in an all-cash merger valued at $73.00 per share. Upon completion, subject to shareholder approval and regulatory clearances, Bio-Techne will become a wholly owned subsidiary of Merck. The deal aims to provide immediate cash value and strategic scale.

Bio-Techne entered into an Agreement and Plan of Merger with Merck, Darmstadt, Germany, under which Merck will acquire Bio-Techne for $73.00 per share in cash. Following the merger, Bio-Techne will become a wholly owned subsidiary of Merck, subject to shareholder approval and customary regulatory clearances. The agreement includes customary terms, closing conditions, and termination fee provisions for both parties.

Agreement details:

Agreement type: Agreement and Plan of Merger (all-cash acquisition)
Counterparty: Merck, Darmstadt, Germany
Signed / Effective: Jun 25 2026 / N/A
Reason: Provide immediate cash value and strategic scale under Merck

Original SEC Filing: BIO-TECHNE Corp [ TECH ] - 8-K - Jun. 25, 2026

Disclaimer

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

RSPH